China Generic Drug Makers Set For Bumper Harvest As Patents Expire
This article was originally published in PharmAsia News
Executive Summary
In 2007, some 35 drugs around the world lost their patent protection. For makers of generics, this presents an $82 billion opportunity. Industry experts see China's drug manufacturers having an edge thanks to their lower production and environmental protection costs, as well as strong ability to clone original products. At the same time, local enterprises face hurdles in the poorer quality of their generic drugs, low-level research and development, and inadequate understanding of the international market. The last shortcoming stems from the language gap in communication, the brief experience of the local industry in globalization, and limited exposure to overseas investment. (Click here for more)
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.